Scopio Labs, a Tel Aviv, Israel-based advanced digital microscopy company, completed a $16m Series B funding round.
The round was led by Olive Tree Ventures with participation from Aurum Ventures, OurCrowd, LR group and others.
The company, which has raised $30m in total funding to date, intends to use the capital to expand commercial operations across human and veterinary care in the United States and Europe, by ramping up manufacturing and sales, and further developing a strong clinical trial pipeline to broaden its portfolio of offerings.
Led by Itai Hayut, co-founder and CEO, Scopio Labs develops a digital microscopy that captures and digitizes full slide microscopy data. Using advanced computational photography techniques to reconstruct data, it offers an automated digital microscopy scanning system with high resolution and quality images in hematology, pathology, research and veterinary medicine.
The closing of the funding round follows the company’s receipt of a CE mark certification for its X100 Full Field Peripheral Blood Smear (PBS) microscopy system, an all-in-one automated in-vitro hematology diagnostic platform that enables remote consultation and includes a computer-vision based decision support system. In addition, A multi-center study in preparation of an FDA submission is being completed.
Earlier this year, the company launched ScopioVet, an end-to-end digital cytology solution for veterinary professionals.